Navigation Links
CytImmune in Medical Technology

CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007

...o 12 noon on June 3. Dr. Lawrence Tamarkin, CEO of cytimmune will present the poster abstract entitled "Prelimi...TNF nanomedicine. "Acceptance to ASCO provides cytimmune the opportunity to present its research to the lea...ology experts," said Dr. Lawrence Tamarkin, CEO of cytimmune Sciences. "For an emerging company, it's a chance ...

CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago

... data of a National Cancer Institute conducted and cytimmune Sciences sponsored Phase 1 trial of CYT-6091 (Auri...vancing cancer therapy." In preclinical studies, cytimmune achieved safe and targeted delivery of TNF at leve...d the ASCO Poster Presentation can be found on the cytimmune website,
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... Researchers have linked increased resistance to bacterial pneumonia in ... sex hormone estrogen. , Females are naturally more resistant ... of scientists has shown that increased resistance to bacterial ... nitric oxide synthase 3 (NOS3). They also show that ... the female sex hormone estrogen. , The team, lead ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
Other Contents